Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Patients and healthcare professionals are asked to report all suspected adverse reactions via the national reporting system.

Belgium:
Federal agency for medicines and health products
Pharmacovigilance
EUROSTATION II, Victor Hortaplein, 40/40, B-1060 Brussels
or
PO Box 97, B-1000 Brussels Madou
Website: www.famhp.be

Grand Duchy of Luxembourg:
Centre Régional de Pharmacovigilance de Nancy - Bâtiment de Biologie Moléculaire et de Biopathologie (BBB)
CHRU de Nancy – Hôpitaux de Brabois
Rue du Morvan – F-54 511 Vandœuvre-lès-Nancy Cedex
ou
Direction de la Santé - Division de la Pharmacie et des Médicaments
Villa Louvigny – Allée Marconi, L-2120 Luxembourg
Site internet: http://www.sante.public.lu/fr/politique-sante/ministere-sante/direction-sante/div-pharmacie-medicaments/index.html